We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
18F-FDG small-animal PET/CT differentiates trastuzumab-responsive from unresponsive human breast cancer xenografts in athymic mice.
- Authors
McLarty, Kristin; Fasih, Aisha; Scollard, Deborah A; Done, Susan J; Vines, Douglass C; Green, David E; Costantini, Danny L; Reilly, Raymond M
- Abstract
Breast cancers (BCs) with high human epidermal growth factor receptor type 2 (HER2) expression are most likely to respond to trastuzumab; however, the mechanisms of action of trastuzumab are complex and there are no established biomarkers to accurately monitor treatment outcome in individual patients. Therefore, our aim was to determine, in human BC xenografts in athymic mice treated with trastuzumab, whether there were any changes in (18)F-FDG uptake that were associated with response to the drug and that could have utility in monitoring response in patients.
- Publication
Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2009, Vol 50, Issue 11, p1848
- ISSN
1535-5667
- Publication type
Journal Article
- DOI
10.2967/jnumed.109.067231